|1.||Arts, Eric J: 2 articles (05/2009 - 07/2004)|
|2.||Hartley, Oliver: 2 articles (11/2008 - 07/2004)|
|3.||Veazey, Ronald S: 1 article (05/2009)|
|4.||Dudley, Dawn M: 1 article (05/2009)|
|5.||Lalonde, Matthew S: 1 article (05/2009)|
|6.||Wentzel, Jennifer L: 1 article (05/2009)|
|7.||Cerini, Fabrice: 1 article (11/2008)|
|8.||Mosier, Donald: 1 article (11/2008)|
|9.||Escola, Jean-Michel: 1 article (11/2008)|
|10.||Gaertner, Hubert: 1 article (11/2008)|
07/01/2004 - "Finally, when CCR5 genetic polymorphism data were integrated with results from the in vitro LC infection studies, PSC-RANTES was found to be equally effective in inhibiting R5 HIV in LC isolated from individuals with CCR5 diplotypes known to be associated with low, intermediate, and high cell surface levels of CCR5. "
05/01/2009 - "This study is the first to describe the immediate selection and infection of a drug-resistant SHIV variant in the face of a protective vaginal microbicide, PSC-RANTES. "
05/01/2009 - "PSC-RANTES binds to CCR5, inhibits human immunodeficiency virus type 1 (HIV-1) entry, and has been shown as a vaginal microbicide to protect rhesus macaques from a simian-human immunodeficiency virus chimera (SHIV(SF162-p3)) infection in a dose-dependent manner. "
07/01/2004 - "PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes."
|2.||HIV Infections (HIV Infection)
07/01/2004 - "In summary, PSC-RANTES is a potent inhibitor of R5 HIV infection in immature LC, suggesting that it may be useful as a topical microbicide to block sexual transmission of HIV."
07/01/2004 - "Next, we found that 20-min preincubation of skin explants with each RANTES analogue blocked R5 HIV infection of LC in a dose-dependent manner (1 to 100 nM) and that PSC-RANTES was the most potent of these compounds. "
07/01/2004 - "Here, we investigated the ability of synthetic RANTES analogues (AOP-, NNY-, and PSC-RANTES) to block R5 HIV infection of human immature LC by using a skin explant model. "
11/18/2008 - "PSC-RANTES is fully protective when applied topically in a macaque model of vaginal HIV transmission, but it has 2 potential disadvantages related to further development: the requirement for chemical synthesis adds to production costs, and its strong CCR5 agonist activity might induce local inflammation. "